Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland

BACKGROUND AND AIMS A previous analysis of hepatitis C virus (HCV)-related healthcare costs in Switzerland found that the annual healthcare costs of untreated HCV infection (excluding antiviral treatment) could increase by more than 25 million Swiss francs (CHF) between 2013 and 2030. Si...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Sarah Blach, Christian Schaetti, Philip Bruggmann, Francesco Negro, Homie Razavi
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2019-03-01
Ráidu:	Swiss Medical Weekly
Fáttát:	Cost-effectiveness direct acting antivirals hepatitis C virus hepatocellular carcinoma liver cirrhosis quality-adjusted life years
Liŋkkat:	https://www.smw.ch/index.php/smw/article/view/2598
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!